Dynamic Journeys: Defining CQA for Oligonucleotide Therapeutics

Time: 8:05 am
day: Pre-Conference Day


In this session embark on an exploration of how CQAs serve as the linchpin, influencing the quality of the final products. Navigate case-studies and unique experiences for hands-on development. Delving into the additional CMC considerations that demand from regulatory compliance to manufacturing scalability, you will unravel the complex landscape of CMC with precision and clarity.

Join this workshop as we delve into:

  • Highlighting essential steps and emphasising crucial considerations when deciding CQA
  • Additional CMC considerations needing to be addressed
  • Identifying assays and the challenges without reference standards, and additional practical implication